Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
therapy approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech has made steady progress, securing access and reimbursement for Vyjuvek since its launch in the United States. As of July, Krystal secured over 575 reimbursement approvals for Vyjuvek in the United States. The company recently received a significant boost when the FDA approved a label update for Vyjuvek (beremagene geperpavec-svdt) that expands the drug's label. The FDA expanded Vyjuvek's eligible patient population to include DEB patients from birth. The latest update also provides patients with greater flexibility in using Vyjuvek, including the ability to manage wound dressings. Patients and caregivers can now administer Vyjuvek at home, making it more convenient. We remind investors that Vyjuvek received approval in the United States in 2023. DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues, caused by on
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech to Present at 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth [Seeking Alpha]Seeking Alpha
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- KRYS's page on the SEC website